Jordan D Berlin
Yale University Cancer Center LAO · Vanderbilt-Ingram Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jordan D Berlin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:06 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03641313 · Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction CancerNational Cancer Institute (NCI) · completed · Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8 · principal investigator
- Ph2NCT00837876 · Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by SurgeryVanderbilt-Ingram Cancer Center · completed · Pancreatic Cancer · principal investigator
- Ph1NCT00573404 · Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal TumorsVanderbilt-Ingram Cancer Center · terminated · Gastrointestinal Stromal Tumor · principal investigator
- Ph2NCT00466505 · Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by SurgeryVanderbilt-Ingram Cancer Center · completed · Colorectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Project 2: Targeting Glutamine Metabolism to Enhance EGFR Blockade in Wild-Type RAS CRCP50CA236733 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · fiscal years 2019 to 2024 · $142,081 awarded in 2024Same name and institution; not confirmed by an ID
- Vanderbilt Network Lead Academic Participating Site for the NCTNUG1CA233270 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · fiscal years 2019 to 2022 · $507,576 awarded in 2022Same name and institution; not confirmed by an ID
- VU PREDICTU24CA220325 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · fiscal years 2018 to 2019 · $630,328 awarded in 2019Same name and institution; not confirmed by an ID
- EARLY PHASE CLINICAL RESEARCH SUPPORT (Core-017)P30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · fiscal years 2010 to 2018 · $7,998 awarded in 2018Grant number is on one of their registry trials
- Vanderbilt Network Lead Academic Participating Site for the NCTNU10CA180847 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · fiscal years 2014 to 2018 · $503,410 awarded in 2018Same name and institution; not confirmed by an ID
- ViKTriY-PC Consortium Phase II SupplementUM1CA186689 · NCI · YALE UNIVERSITY · fiscal years 2016 · $732,368 awarded in 2016Grant number is on one of their registry trials
- Targeting K-Ras in CRCP50CA095103 · NCI · VANDERBILT UNIVERSITY · fiscal years 2012 to 2015 · $281,462 awarded in 2015Same name and institution; not confirmed by an ID
- Eastern Cooperative Oncology GroupU10CA049957 · NCI · VANDERBILT UNIVERSITY · fiscal years 2010 to 2013 · $291,047 awarded in 2013Same name and institution; not confirmed by an ID
- PS-341 in Hepatocellular Carcinoma: A Phase II TrialR21CA099269 · NCI · VANDERBILT UNIVERSITY · fiscal years 2003 to 2004 · $312,833 awarded in 2004Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:06 UTC. The ranking covers the 200 most relevant of 40 PubMed records, and a shared surname and initials can bring in a namesake. All 40 on PubMed
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.Lancet Oncol · 2020856 citationsRCR 36.6
- 628 citationsRCR 13.2
- 540 citationsRCR 13.1
- 366 citationsRCR 18.9
- Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.J Clin Oncol · 2005118 citationsRCR 2.3
- Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.J Clin Oncol · 201796 citationsRCR 2.9
- A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.Cancer Chemother Pharmacol · 201790 citationsRCR 2.9
- 70 citationsRCR 2.2
- 64 citationsRCR 1.6
- Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer.Radiother Oncol · 201657 citationsRCR 1.7